BR112015028302A2 - formulação de pastilha de nicotina - Google Patents

formulação de pastilha de nicotina

Info

Publication number
BR112015028302A2
BR112015028302A2 BR112015028302A BR112015028302A BR112015028302A2 BR 112015028302 A2 BR112015028302 A2 BR 112015028302A2 BR 112015028302 A BR112015028302 A BR 112015028302A BR 112015028302 A BR112015028302 A BR 112015028302A BR 112015028302 A2 BR112015028302 A2 BR 112015028302A2
Authority
BR
Brazil
Prior art keywords
nicotine
tablet formulation
nicotine tablet
synthetic
water soluble
Prior art date
Application number
BR112015028302A
Other languages
English (en)
Inventor
Ramchandra Dipali Satish
Ahmad Pathan Shadab
Bindra Narang Sumeet
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112015028302A2 publication Critical patent/BR112015028302A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo “formulação de pastilha de nicotina” os aspectos da presente invenção são direcionados a uma pastilha de nicotina para administração oral compreendendo: um ativo de nicotina; pelo menos um polímero não iônico semissintético ou sintético solúvel em água de alta viscosidade; e pelo menos um polímero não iônico semissintético ou sintético solúvel em água de baixa viscosidade. as pastilhas da presente invenção são mais estáveis e menos caras do que as pastilhas tradicionais.
BR112015028302A 2013-05-10 2014-05-09 formulação de pastilha de nicotina BR112015028302A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1398DE2013 2013-05-10
PCT/US2014/037421 WO2014182983A1 (en) 2013-05-10 2014-05-09 Nicotine lozenge formulation

Publications (1)

Publication Number Publication Date
BR112015028302A2 true BR112015028302A2 (pt) 2017-07-25

Family

ID=51867761

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015028302A BR112015028302A2 (pt) 2013-05-10 2014-05-09 formulação de pastilha de nicotina

Country Status (12)

Country Link
US (1) US20160113868A1 (pt)
EP (1) EP2994136B1 (pt)
JP (1) JP2016518413A (pt)
CN (1) CN105263493A (pt)
AR (1) AR096223A1 (pt)
AU (2) AU2014262579B2 (pt)
BR (1) BR112015028302A2 (pt)
CA (1) CA2912223C (pt)
DK (1) DK2994136T3 (pt)
MX (1) MX2015015537A (pt)
TW (1) TW201507726A (pt)
WO (1) WO2014182983A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170172995A1 (en) * 2015-09-08 2017-06-22 Venkateswara Rao Repaka Pharmaceutical compositions of Nicotine and process for preparation thereof
WO2019244176A1 (en) * 2018-06-23 2019-12-26 Strides Shasun Limited Stable nicotine lozenges
CN112444466B (zh) * 2019-09-05 2023-02-28 上海新型烟草制品研究院有限公司 一种用于评价口含烟烟碱体外吸收的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
GB8615676D0 (en) 1986-06-26 1986-07-30 Stoppers Co Ltd Nicotine containing lozenge
US5110605A (en) 1990-08-21 1992-05-05 Oramed, Inc. Calcium polycarbophil-alginate controlled release composition and method
US5135753A (en) * 1991-03-12 1992-08-04 Pharmetrix Corporation Method and therapeutic system for smoking cessation
US5549906A (en) 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
HU224035B1 (hu) 1996-05-13 2005-05-30 Novartis Consumer Health S.A. Bukkális adagolórendszer
US6358060B2 (en) * 1998-09-03 2002-03-19 Jsr Llc Two-stage transmucosal medicine delivery system for symptom relief
PL364621A1 (en) * 2001-03-26 2004-12-13 Smithkline Beecham Corporation Nicotine-containing oral dosage form
NO346973B1 (en) * 2002-12-20 2023-03-20 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
DK1695094T3 (da) * 2003-10-24 2013-09-16 Adhesives Res Inc Disintegrerende film til diagnostiske indretninger
US20100061940A1 (en) 2006-03-16 2010-03-11 Niconovum Ab Chewing Gum Compositions Providing Rapid Release of Nicotine
CN101437496A (zh) * 2006-03-16 2009-05-20 尼科诺瓦姆股份公司 提供尼古丁快速释放的稳定锭剂组合物
US20080260836A1 (en) * 2007-04-18 2008-10-23 Thomas James Boyd Films Comprising a Plurality of Polymers
AR071420A1 (es) * 2008-05-01 2010-06-16 Smithkline Beecham Corp Composicion de pastilla para chupar oral que comprende un principio activo de nicotina y procedimiento para fabricarla
MX344033B (es) * 2010-06-30 2016-12-01 Colgate-Palmolive Company * Peliculas de multicapas para la liberacion del sabor.
SG194605A1 (en) * 2011-05-06 2013-12-30 Glaxosmithkline Llc Sustained release paracetamol formulations

Also Published As

Publication number Publication date
EP2994136A1 (en) 2016-03-16
CN105263493A (zh) 2016-01-20
MX2015015537A (es) 2016-02-09
TW201507726A (zh) 2015-03-01
JP2016518413A (ja) 2016-06-23
CA2912223A1 (en) 2014-11-13
US20160113868A1 (en) 2016-04-28
EP2994136A4 (en) 2016-10-26
WO2014182983A1 (en) 2014-11-13
AR096223A1 (es) 2015-12-16
AU2014262579B2 (en) 2017-06-01
CA2912223C (en) 2021-08-31
AU2017203121A1 (en) 2017-06-01
AU2014262579A1 (en) 2015-11-26
AU2017203121B2 (en) 2019-02-21
EP2994136B1 (en) 2020-11-18
DK2994136T3 (da) 2021-02-01

Similar Documents

Publication Publication Date Title
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
NZ726746A (en) Stable cannabinoid formulations
NI201500059A (es) Inhibidores de la tirosina-quinasa de bruton
CL2019002190A1 (es) Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984)
BR112018076169A2 (pt) derivados azabenzimidazol como inibidores de pi3k beta
CL2016001604A1 (es) “compuestos derivados de pirazolo[1,5-a]piridina, inhibidores de quinasas axl y c-met; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
EA201591004A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201501032A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
BR112016002233A2 (pt) composições de adoçante
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
MA44637A1 (fr) Composes hétérocycliques et leurs utilisations
BR112016008576A2 (pt) Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária
AR098168A1 (es) Formulación estable de insulina glulisina
EA201792487A1 (ru) Композиции гидроксипропил-бета-циклодекстринов и способы
BR112015018504A2 (pt) moduladores de flap
DOP2016000007A (es) Pirazolpiridinas sustituidas
BR112018007068A2 (pt) derivados de quinoxalina e piridopirazina como inibidores de pi3kbeta
MX2015017202A (es) Formulacion de liberacion modificada.
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
BR112015028302A2 (pt) formulação de pastilha de nicotina
AR112448A1 (es) Derivados de xantina sustituidos
MX2015010486A (es) Composicion masticable para administracion oral y proceso para preparar la misma.
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired
B350 Update of information on the portal [chapter 15.35 patent gazette]